Audentes Therapeutics (BOLD) Receives New Coverage from Analysts at B. Riley

Share on StockTwits

B. Riley began coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report released on Friday morning, Marketbeat.com reports. The brokerage issued a sell rating and a $20.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on BOLD. HC Wainwright set a $40.00 price target on Audentes Therapeutics and gave the company a buy rating in a research report on Wednesday, August 8th. BidaskClub downgraded Audentes Therapeutics from a buy rating to a hold rating in a research report on Thursday, June 28th. Chardan Capital began coverage on Audentes Therapeutics in a research report on Monday, June 25th. They set a neutral rating and a $35.00 price target for the company. William Blair reissued a buy rating on shares of Audentes Therapeutics in a research report on Tuesday, August 7th. Finally, Mizuho reissued a buy rating and set a $45.00 price target on shares of Audentes Therapeutics in a research report on Wednesday, August 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. Audentes Therapeutics currently has a consensus rating of Hold and an average price target of $36.17.

BOLD stock traded down $2.09 during trading on Friday, reaching $35.01. 1,186,528 shares of the stock traded hands, compared to its average volume of 246,324. Audentes Therapeutics has a 52-week low of $22.75 and a 52-week high of $46.18. The company has a market cap of $1.38 billion, a PE ratio of -10.30 and a beta of 0.77.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.07). equities analysts predict that Audentes Therapeutics will post -3.38 earnings per share for the current fiscal year.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 71,048 shares of the business’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $39.55, for a total transaction of $2,809,948.40. Following the transaction, the chief executive officer now owns 19,599 shares in the company, valued at $775,140.45. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Matthew R. Patterson sold 26,901 shares of the business’s stock in a transaction dated Tuesday, July 3rd. The stock was sold at an average price of $40.05, for a total value of $1,077,385.05. Following the transaction, the chief executive officer now owns 19,599 shares in the company, valued at approximately $784,939.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 154,494 shares of company stock worth $6,185,904. 6.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. American International Group Inc. lifted its stake in shares of Audentes Therapeutics by 15.9% during the first quarter. American International Group Inc. now owns 12,829 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 1,761 shares in the last quarter. Tocqueville Asset Management L.P. lifted its stake in shares of Audentes Therapeutics by 12.8% during the second quarter. Tocqueville Asset Management L.P. now owns 16,750 shares of the biotechnology company’s stock worth $640,000 after purchasing an additional 1,900 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Audentes Therapeutics by 19.5% in the first quarter. The Manufacturers Life Insurance Company now owns 15,630 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 2,555 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Audentes Therapeutics by 27.4% in the first quarter. Rhumbline Advisers now owns 17,008 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 3,657 shares in the last quarter. Finally, Tortoise Investment Management LLC acquired a new position in shares of Audentes Therapeutics in the first quarter worth about $112,000. Institutional investors own 96.75% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: What does RSI mean?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply